Cargando…
TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis
OBJECTIVE: To assess the efficacy of tumour necrosis factor-α (TNF-α) inhibitors used as steroid-sparing monotherapy in central nervous system (CNS) parenchymal sarcoidosis. METHODS: The French Multiple Sclerosis and Neuroinflammation Centers retrospectively identified patients with definite or prob...
Autores principales: | Hilezian, Frédéric, Maarouf, Adil, Boutiere, Clemence, Rico, Audrey, Demortiere, Sarah, Kerschen, Philippe, Sene, Thomas, Bensa-Koscher, Caroline, Giannesini, Claire, Capron, Jean, Mekinian, Arsene, Camdessanché, Jean-Philippe, Androdias, Géraldine, Marignier, Romain, Collongues, Nicolas, Casez, Olivier, Coclitu, Catalina, Vaillant, Mathieu, Mathey, Guillaume, Ciron, Jonathan, Pelletier, Jean, Audoin, Bertrand |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292597/ https://www.ncbi.nlm.nih.gov/pubmed/34103339 http://dx.doi.org/10.1136/jnnp-2020-325665 |
Ejemplares similares
-
Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception
por: Demortiere, Sarah, et al.
Publicado: (2023) -
Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?
por: Poullet, Zélia, et al.
Publicado: (2022) -
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases
por: Avouac, Alexandre, et al.
Publicado: (2021) -
Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
por: Claverie, Roxane, et al.
Publicado: (2023) -
Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
por: Maarouf, Adil, et al.
Publicado: (2020)